NextSharkNextShark.com

Chinese ‘Viagra’ Maker Claims 140 Million Chinese Men Are Impotent, Stocks Soar

Chinese ‘Viagra’ Maker Claims 140 Million Chinese Men Are Impotent, Stocks Soar

May 18, 2018
SHARE
A company in China that manufactures a viagra-like drug saw its stocks increase sharply after publishing a report that 140 million men in the country are suffering from erectile dysfunction.
The drug maker, Hebei Changshan Biochemical Pharmaceutical, announced on Tuesday that its subsidiary firm in Jiangsu province has been licensed to produce sildenafil citrate, the active ingredient in Viagra.
In breaking the news, it added that 140 million men in China have erectile dysfunction, which translates to one in five males, according to the Global Times.
Changshan Biochemical’s share price then rose to its maximum daily limit of 10% on the Shenzhen Stock Exchange on May 16. Further gains were recorded in trading the following day.
Subscribe to
NextShark's Newsletter

A daily dose of Asian America's essential stories, in under 5 minutes.

Get our collection of Asian America's most essential stories to your inbox daily for free.

Unsure? Check out our Newsletter Archive.

The company, part of China’s hi-tech enterprise program, has received funding from the Ministry of Finance and the National Development and Reform Commission, the country’s economic planning agency.
In a statement, Changshan Biochemical clarified that the statistic came from a 2014 report by Guosen Securities, a state-owned financial services firm. It was not subjected to verification.
The South China Morning Post quoted the company as saying:
“The company has obtained the relevant approval for production of sildenafil citrate tablets, but the new product’s market size, promotion and market share may be lower than expected.
“The future sales of this product has great uncertainty and there is a risk of increased market competition for this product. Investors are advised to make prudent decisions and pay attention to investment risks.”
Du Zuoyuan, author of the Guosen report, then admitted that the data came from Wang Xiaofeng, a Peking University urologist who claimed in 2010 that the overall morbidity rate for erectile dysfunction among Chinese men was 26.1% — and 40.2% among those aged 40 and above.
MOST READ
    HAPPENING NOW
      Carl Samson

      Carl Samson is a Senior Editor for NextShark

      SHARE THIS ARTICLE:

      RELATED STORIES FROM NEXTSHARK

      Support
      NextShark's
      Journalism

      Many people might not know this, but NextShark is a small media startup that runs on no outside funding or loans, and with no paywalls or subscription fees, we rely on help from our community and readers like you.

      Everything you see today is built by Asians, for Asians to help amplify our voices globally and support each other. However, we still face many difficulties in our industry because of our commitment to accessible and informational Asian news coverage.

      We hope you consider making a contribution to NextShark so we can continue to provide you quality journalism that informs, educates, and inspires the Asian community. Even a $1 contribution goes a long way. Thank you for supporting NextShark and our community.

      © 2023 NextShark, Inc. All rights reserved.